Trial of Rituximab for Graves' Ophthalmopathy

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Thyroid-associated Ophthalmopathy

In brief

This study is being done to investigate the effects (good and bad) of Rituximab for the treatment of an autoimmune eye disease called Graves' ophthalmopathy. This disease has proven to be difficult to treat. Rituximab is a monoclonal antibody that depletes a line of cells involved in the autoimmune response. The study hypotheses is that rituximab is effective in the treatment of patients with moderate to severe active Graves' ophthalmopathy.

Key facts

Study ID
NCT00595335
Run by
Rebecca Bahn
People needed
25
Starts
2008-04-01
Expected to finish
2013-09-01
Last updated by the study team
2016-01-01

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.